A minimal (<1%) long-term risk of MDS and AML was seen in clinical trials [17]. In a meta-analysis evaluating the efficacy and safety of PARP inhibitors, utilized either concomitantly or independently of chemotherapy, compared to chemotherapy alone for advanced BC, a noteworthy observation was that severe adverse effects (grade ≥3) were more prevalent in regimens incorporating PARP inhibitors than in chemotherapy-alone protocols. The gene discussed is PARP1; the disease is myelodysplastic syndrome.